BridgeBio has demonstrably improved its development of the innovative solution for ATTR-CM, leveraging the compound. Initial patient data suggests promising improvements for individuals diagnosed with this debilitating https://attr-cm861113.digiblogbox.com/66521005/bridgebio-advances-amyloidosis-therapy-using-the-drug